GNLKQ (Genelink) FCF Margin %: -22.37% (As of Sep. 2013)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Genelink FCF Margin %?

Genelink GNLKQ FCF Margin % is -22.37% as of Sep. 2013.

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Genelink's Free Cash Flow for the three months ended in Sep. 2013 was $-0.07 Mil. Genelink's Revenue for the three months ended in Sep. 2013 was $0.30 Mil. Therefore, Genelink's FCF Margin % for the quarter that ended in Sep. 2013 was -22.37%.

As of today, Genelink's current FCF Yield % is 0.00%.

The historical rank and industry rank for Genelink's FCF Margin % or its related term are showing as below:

GNLKQ' s FCF Margin % Range Over the Past 10 Years
Min: 0   Med: 0   Max: 0
Current: -65.7

GNLKQ's FCF Margin % is not ranked
in the Biotechnology industry.
Industry Median: -78.14 vs GNLKQ: -65.70

Genelink FCF Margin % Related Terms

Genelink FCF Margin % Historical Data

* Premium members only.

The historical data trend for Genelink's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Genelink FCF Margin % Chart

Genelink Annual Data
Trend Dec03 Dec04 Dec05 Dec06 Dec07 Dec08 Dec09 Dec10 Dec11 Dec12
FCF Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -27.16 -31.20 -18.67 -62.80 -122.94

Genelink Quarterly Data
Dec08 Mar09 Jun09 Sep09 Dec09 Mar10 Jun10 Sep10 Dec10 Mar11 Jun11 Sep11 Dec11 Mar12 Jun12 Sep12 Dec12 Mar13 Jun13 Sep13
FCF Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -154.12 -186.65 -36.75 -24.76 -22.37

GNLKQ vs VITIF, HSTC, NTRR: FCF Margin % Comparison

For the Biotechnology subindustry, Genelink's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Genelink FCF Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Genelink's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Genelink's FCF Margin % falls into.


Genelink FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Genelink's FCF Margin for the fiscal year that ended in Dec. 2012 is calculated as

FCF Margin=Free Cash Flow (A: Dec. 2012 )/Revenue (A: Dec. 2012 )
=-2.626/2.136
=-122.94 %

Genelink's FCF Margin for the quarter that ended in Sep. 2013 is calculated as

FCF Margin=Free Cash Flow (Q: Sep. 2013 )/Revenue (Q: Sep. 2013 )
=-0.066/0.295
=-22.37 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about FCF Margin % →
What does a FCF Margin % of -22.37% mean?
Genelink (GNLKQ) has a FCF Margin % of -22.37% as of Sep. 2013. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Genelink and its competitors.
Is Genelink's FCF Margin % too high?
Genelink's current FCF Margin % is -22.37%.
How does Genelink's FCF Margin % compare to VITIF and HSTC?
Genelink's FCF Margin % of -22.37% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Biotechnology company?
A good FCF Margin % depends on the Biotechnology industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Genelink and its competitors. Genelink's current FCF Margin % is -22.37%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genelink stock overvalued right now?
Genelink (GNLKQ) has a current FCF Margin % of -22.37%. The current FCF Margin % is -22.37%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Genelink (GNLKQ), the current FCF Margin % is -22.37% as of Sep. 2013. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Genelink Business Description

Address 8250 Exchange Drive, Suite 120, Orlando, FL, USA, 32809
Genelink Inc is a genetics-based, personal healthcare firm that has developed DNA assessments measuring personal DNA tendencies. These small differences in DNA, called SNPs can indicate genetic variants, the protein products of which may not be performing at optimal levels and can be linked to aging and other wellness issues. The company's scientists use the DNA assessments information from each client to formulate products to optimize health and wellness within normal ranges. The company has a compilation of issued and pending patents that center on using DNA analysis for the purpose of customizing nutrition and skin care formulations for wellness and anti-aging.